PTC Therapeutics Pulls Translarna NDA After FDA Flags Weak Efficacy Evidence
PTC Therapeutics withdrew its NDA resubmission for Translarna (ataluren), a therapy for nonsense mutation Duchenne muscular dystrophy, after the FDA said the data likely failed to show substantial evidence of effectiveness. This follows the EMA CHMP’s March 2025 decision not to renew Translarna’s authorization, ending over 20 years of development.
1. Regulatory Withdrawal of Translarna NDA
PTC Therapeutics withdrew the New Drug Application resubmission for Translarna following FDA feedback indicating the clinical data did not demonstrate substantial evidence of effectiveness for treating nonsense mutation Duchenne muscular dystrophy. This decision halts U.S. approval prospects and delays potential market entry.
2. European Setback on Translarna Authorization
In March 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency opted not to renew Translarna’s marketing authorization, citing unresolved efficacy concerns. With no EU approval and U.S. prospects stalled, the therapy faces significant regulatory barriers across major markets.
3. Implications for PTC Therapeutics
The withdrawal marks a major setback after more than 20 years of research investment, likely affecting PTC’s revenue outlook and pressuring its share price. Analysts may revise earnings forecasts and valuation as the company reevaluates its pipeline and strategic priorities.